Background: Intestinal symptoms are common in patients with hidradenitis suppurativa (HS). HS patients may experience a broad spectrum of chronic inflammatory intestinal disorders (CIID), not exclusive to inflammatory bowel diseases, which are diagnosed by colonoscopy and intestinal biopsies. The frequency of CIID in patients with HS has not been investigated. Objective: The objectives of this study were to determine the occurrence of CIID in HS and characterize this clinical population. Furthermore, the feasibility of using faecal calprotectin (FC) test or anti-Saccharomyces cerevisiae antibody (ASCA) levels to assess the colonic inflammation of CIID in HS patients was investigated. Methods: All newly diagnosed and untreated HS patients (n = 74) were referred to a gastroenterologist for FC followed by colonoscopy after informed consent. C-reactive protein (CRP), white blood cell count, nucleotide-binding oligomerization-domain-containing protein 2 (NOD2) polymorphism, and ASCA levels were measured. Patients were divided into HS-only and HS with CIID (HS + CIID) groups, based on the absence or presence of CIID. Laboratory and clinical parameters (age, gender, HS onset, clinical stage, family history, body mass index (BMI), smoking) were compared between the groups. Results: Thirteen patients complained gastrointestinal symptoms prior to any examination, including 11 in the HS + CIID group. The CIID frequency in HS was 28.4% (n = 21/74), based on colonoscopy and histology. Significantly more patients had severe disease state in the HS + CIID group compared with the HS-only group, and BMI was significantly lower in the HS + CIID group (28.20 ± 5.58 vs. 32.74 ± 6.45, p = 0.006). FC positivity occurred significantly more in HS + CIID patients compared with HS-only patients (90.48% vs. 3.77%, p < 0.001), and ASCA IgG levels were significantly elevated in HS + CIID patients (22.08 ± 23.07 vs. 8.41 ± 10.94 U/mL, p = 0.001). The FC test identified HS + CIID patients with 96.23% specificity and 91.3% sensitivity, while ASCA displayed 77.8% sensitivity and 76.3% specificity. Blood count, CRP, and the presence of NOD2 polymorphisms were indifferent between the two groups. Conclusion: A high frequency of CIID was detected in the examined HS population. The noninvasive FC test has high sensitivity and specificity for diagnosing CIID in HS patients. Concomitant CIID and HS may indicate the need for an early-start for biological treatment.

1.
Orenstein
LAV
,
Nguyen
TV
,
Damiani
G
,
Sayed
C
,
Jemec
GBE
,
Hamzavi
I
.
Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice
.
Dermatology
.
2020
;
236
(
5
):
393
412
.
2.
Nguyen
TV
,
Damiani
G
,
Orenstein
LAV
,
Hamzavi
I
,
Jemec
GB
.
Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life
.
J Eur Acad Dermatol Venereol
.
2021
;
35
(
1
):
50
61
.
3.
Saunte
DML
,
Jemec
GBE
.
Hidradenitis suppurativa: advances in diagnosis and treatment
.
JAMA
.
2017
;
318
(
20
):
2019
32
.
4.
Jfri
A
,
Nassim
D
,
O’Brien
E
,
Gulliver
W
,
Nikolakis
G
,
Zouboulis
CC
.
Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis
.
JAMA Dermatol
.
2021
;
157
(
8
):
924
31
.
5.
Sabat
R
,
Jemec
GBE
,
Matusiak
Ł
,
Kimball
AB
,
Prens
E
,
Wolk
K
.
Hidradenitis suppurativa
.
Nat Rev Dis Primers
.
2020
;
6
(
1
):
18
.
6.
Duchatelet
S
,
Miskinyte
S
,
Delage
M
,
Ungeheuer
MN
,
Lam
T
,
Benhadou
F
.
Low prevalence of GSC gene mutations in a large cohort of predominantly caucasian patients with hidradenitis suppurativa
.
J Invest Dermatol
.
2020
;
140
(
10
):
2085
8.e14
.
7.
Radhakrishna
U
,
Ratnamala
U
,
Jhala
DD
,
Vadsaria
N
,
Patel
M
,
Uppala
LV
.
Cytochrome P450 genes mediated by DNA methylation are involved in the resistance to hidradenitis suppurativa
.
J Invest Dermatol
.
2023
;
143
(
4
):
670
3.e19
.
8.
Radhakrishna
U
,
Ratnamala
U
,
Jhala
DD
,
Vadsaria
N
,
Patel
M
,
Uppala
LV
.
Methylated miRNAs may serve as potential biomarkers and therapeutic targets for hidradenitis suppurativa
.
J Eur Acad Dermatol Venereol
.
2022
;
36
(
11
):
2199
213
.
9.
Christopoulos
PF
,
Gjølberg
TT
,
Krüger
S
,
Haraldsen
G
,
Andersen
JT
,
Sundlisæter
E
.
Targeting the Notch signaling pathway in chronic inflammatory diseases
.
Front Immunol
.
2021
;
12
:
668207
.
10.
Deckers
IE
,
Benhadou
F
,
Koldijk
MJ
,
Del Marmol
V
,
Horváth
B
,
Boer
J
.
Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study
.
J Am Acad Dermatol
.
2017
;
76
(
1
):
49
53
.
11.
Egeberg
A
,
Jemec
GBE
,
Kimball
AB
,
Bachelez
H
,
Gislason
GH
,
Thyssen
JP
.
Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa
.
J Invest Dermatol
.
2017
;
137
(
5
):
1060
4
.
12.
Abraham
C
,
Cho
JH
.
Inflammatory bowel disease
.
N Engl J Med
.
2009
;
361
(
21
):
2066
78
.
13.
Ricciuto
A
,
Griffiths
AM
.
Clinical value of fecal calprotectin
.
Crit Rev Clin Lab Sci
.
2019
;
56
(
5
):
307
20
.
14.
Schembri
J
,
Bonello
J
,
Christodoulou
DK
,
Katsanos
KH
,
Ellul
P
.
Segmental colitis associated with diverticulosis: is it the coexistence of colonic diverticulosis and inflammatory bowel disease
.
Ann Gastroenterol
.
2017
;
30
(
3
):
257
61
.
15.
Wickbom
A
,
Bohr
J
,
Nyhlin
N
,
Eriksson
A
,
Lapidus
A
,
Münch
A
.
Microscopic colitis in patients with ulcerative colitis or Crohn’s disease: a retrospective observational study and review of the literature
.
Scand J Gastroenterol
.
2018
;
53
(
4
):
410
6
.
16.
Tulassay
Z
,
Mihaly
E
,
Herszényi
L
.
Microscopic colitis: a challenging disorder
.
Dig Dis
.
2020
;
38
(
2
):
117
21
.
17.
Flynn
S
,
Eisenstein
S
.
Inflammatory bowel disease presentation and diagnosis
.
Surg Clin North Am
.
2019
;
99
(
6
):
1051
62
.
18.
Vavricka
SR
,
Spigaglia
SM
,
Rogler
G
,
Pittet
V
,
Michetti
P
,
Felley
C
.
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease
.
Inflamm Bowel Dis
.
2012
;
18
(
3
):
496
505
.
19.
Kehl-Fie
TE
,
Chitayat
S
,
Hood
MI
,
Damo
S
,
Restrepo
N
,
Garcia
C
.
Nutrient metal sequestration by calprotectin inhibits bacterial superoxide defense, enhancing neutrophil killing of Staphylococcus aureus
.
Cell Host Microbe
.
2011
;
10
(
2
):
158
64
.
20.
Ometto
F
,
Friso
L
,
Astorri
D
,
Botsios
C
,
Raffeiner
B
,
Punzi
L
.
Calprotectin in rheumatic diseases
.
Exp Biol Med
.
2017
;
242
(
8
):
859
73
.
21.
Almansouri
D
,
Zouboulis
C
.
Calprotectin functions in the skin: an overview
.
Hong Kong J Dermatol Venereol
.
2017
;
25
:
115
21
.
22.
Kaul
A
,
Hutfless
S
,
Liu
L
,
Bayless
TM
,
Marohn
MR
,
Li
X
.
Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis
.
Inflamm Bowel Dis
.
2012
;
18
(
10
):
1872
84
.
23.
Cheng
L
,
Li
L
,
Liu
C
,
Yan
S
,
Li
Y
.
Meta-analysis of anti-Saccharomyces cerevisiae antibodies as diagnostic markers of Behçet’s disease with gastrointestinal involvement
.
BMJ Open
.
2020
;
10
(
10
):
e033880
.
24.
Barta
Z
,
Csípõ
I
,
Szabó
GG
,
Szegedi
G
.
Seroreactivity against Saccharomyces cerevisiae in patients with Crohn’s disease and celiac disease
.
World J Gastroenterol
.
2003
;
9
(
10
):
2308
12
.
25.
Konrad
A
,
Rütten
C
,
Flogerzi
B
,
Styner
M
,
Göke
B
,
Seibold
F
.
Immune sensitization to yeast antigens in ASCA-positive patients with Crohn’s disease
.
Inflamm Bowel Dis
.
2004
;
10
(
2
):
97
105
.
26.
Assan
F
,
Gottlieb
J
,
Tubach
F
,
Lebbah
S
,
Guigue
N
,
Hickman
G
.
Anti-Saccharomyces cerevisiae IgG and IgA antibodies are associated with systemic inflammation and advanced disease in hidradenitis suppurativa
.
J Allergy Clin Immunol
.
2020
;
146
(
2
):
452
5.e5
.
27.
Zouboulis
CC
,
Tzellos
T
,
Kyrgidis
A
,
Jemec
GBE
,
Bechara
FG
,
Giamarellos-Bourboulis
EJ
.
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity
.
Br J Dermatol
.
2017
;
177
(
5
):
1401
9
.
28.
Shalom
G
,
Freud
T
,
Ben Yakov
G
,
Khoury
R
,
Dreiher
J
,
Vardy
DA
.
Hidradenitis suppurativa and inflammatory bowel disease: a cross-sectional study of 3,207 patients
.
J Invest Dermatol
.
2016
;
136
(
8
):
1716
8
.
29.
Garg
A
,
Hundal
J
,
Strunk
A
.
Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States
.
JAMA Dermatol
.
2018
;
154
(
7
):
814
8
.
30.
Gold
DA
,
Nicholson
C
,
Jacobsen
G
,
Hamzavi
IH
.
International Classification of Diseases-based analysis is inaccurate in assessing the prevalence of inflammatory bowel disease in patients with hidradenitis suppurativa
.
J Am Acad Dermatol
.
2021
;
85
(
2
):
495
7
.
31.
Stange
EF
,
Travis
SP
,
Vermeire
S
,
Beglinger
C
,
Kupcinkas
L
,
Geboes
K
.
European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis
.
Gut
.
2006
55
Suppl 1
i1
15
.
32.
van der Zee
HH
,
Horvath
B
,
Jemec
GBE
,
Prens
EP
.
The association between hidradenitis suppurativa and crohn’s disease: in search of the missing pathogenic link
.
J Invest Dermatol
.
2016
;
136
(
9
):
1747
8
.
33.
Graziano
EJ
,
Vaughn
BP
,
Wang
Q
,
Chow
LS
,
Campbell
JP
.
Microscopic colitis is not an independent risk factor for low bone density
.
Dig Dis Sci
.
2021
;
66
(
10
):
3542
7
.
34.
Khalili
H
,
Burke
KE
,
Roelstraete
B
,
Sachs
MC
,
Olén
O
,
Ludvigsson
JF
.
Microscopic colitis and risk of inflammatory bowel disease in a nationwide cohort study
.
Gastroenterology
.
2020
;
158
(
6
):
1574
83.e2
.
35.
Gambichler
T
,
Hessam
S
,
Skrygan
M
,
Bakirtzi
M
,
Kasakovski
D
,
Bechara
FG
.
NOD2 signalling in hidradenitis suppurativa
.
Clin Exp Dermatol
.
2021
;
46
(
8
):
1488
94
.
36.
Negroni
A
,
Pierdomenico
M
,
Cucchiara
S
,
Stronati
L
.
NOD2 and inflammation: current insights
.
J Inflamm Res
.
2018
;
11
:
49
60
.
37.
Walsham
NE
,
Sherwood
RA
.
Fecal calprotectin in inflammatory bowel disease
.
Clin Exp Gastroenterol
.
2016
;
9
:
21
9
.
38.
Eşer
E
,
Engin
B
,
Yüksel
P
,
Kocazeybek
BS
,
Kutlubay
Z
,
Serdaroğlu
S
.
Relationship between fecal calprotectin level and disease activity in patients with hidradenitis suppurativa
.
Dermatol Ther
.
2020
;
33
(
2
):
e13232
.
39.
Kluger
N
,
Salava
A
,
Lybeck
E
,
Kiiski
LL
,
Nuutinen
P
,
Ruohoalho
T
.
Faecal calprotectin in hidradenitis suppurativa: a study of 55 patients
.
Eur J Dermatol
.
2020
;
30
(
4
):
422
4
.
40.
Lloyd-McLennan
AM
,
Ali
S
,
Kittler
NW
.
Prevalence of inflammatory bowel disease among pediatric patients with hidradenitis suppurativa and the potential role of screening with fecal calprotectin
.
Pediatr Dermatol
.
2021
;
38
(
1
):
98
102
.
You do not currently have access to this content.